Fierce Pharma19h
For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty
The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
Healthline23d
Elevidys (delandistrogene moxeparvovec) Cost and Financial Assistance
The price you pay for Elevidys may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...
Monthly Prescribing Reference15d
Patient Dies Following Treatment With DMD Gene Therapy Elevidys
The patient in this case had suffered acute liver failure following the Elevidys infusion. Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy (DMD) who received ...
Seeking Alpha15d
Sarepta plunges after death linked to Elevidys (update)
Gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT) lost ~20% on Tuesday to reach a new 52-week low after the company disclosed the death of a patient treated with Elevidys, its FDA-approved ...
FiercePharma16d
Sarepta reports one death after patient received DMD gene therapy Elevidys
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech said (PDF) Tuesday. The patient suffered ...
Benzinga.com16d
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
Sarepta reported a patient death from acute liver failure after Elevidys treatment, though no new safety signal was identified. Over 800 patients have received Elevidys, and a recent CMV infection ...
Business Insider16d
Analysts remain optimistic about Elevidys after Sarepta reports patient death
Shares of Sarepta Therapeutics (SRPT) are under pressure on Tuesday after the company shared a safety update related to its Elevidys, the only approved gene therapy in patients with Duchenne ...
Seeking Alpha15d
Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Sarepta Therapeutics stock dropped over 20% after a patient treated with Elevidys for DMD died from acute liver failure, raising safety concerns. Despite the incident, Sarepta maintains that the ...
Yahoo Finance16d
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
On Tuesday, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with ...
Business Insider16d
BofA says Elevidys risk-reward favorable despite Sarepta report of patient death
After Sarepta (SRPT) reported the death of a Duchenne muscular dystrophy patient following treatment with Elevidys after suffering acute liver failure, BofA notes that acute liver failure is a ...
Phys.org24d
Molecular 3D structure of viral 'copying machine' deciphered
Researchers led by Prof. Dr. Hauke Hillen, head of the "Structure and Function of Molecular Machines" research group at the Department of Cellular Biochemistry at the University Medical Center ...